Metformin FDC formulations marketed in India.

Sales volume (millions of tablets/capsules) and value (millions of Rupees [US dollars]) in amounts and as proportions of total volume and value; numbers of branded products of each formulation on the market by October 2012 (numbers of products with sales recorded in 2011–2012); market launch date for the first FDC product; CDSCO first approval date for the original formulation; approval of the FDC in UK and/or US (N = not approved; Y = approved). FDC formulations on the market with and without a record of CDSCO approval are termed respectively “approved” and “unapproved”. Data sources: PharmaTrac; CDSCO-published list of FDC approvals 1961–February 2013. Conversion rate: INR 1 INR = US$0.016. Small differences in totals arise from rounding.*Glibenclamide is known as glyburide in the US.**Rosiglitazone approval withdrawn in India 2005.~Sales recorded in preceding years.Metformin FDC formulations marketed in India.